Myeloproliferative Neoplasms clinical trials at UC Davis
2 research studies open to eligible people
A Study of Oral LY3410738 in Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
open to eligible people ages 18 years and up
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy
Sacramento, California and other locations
EVERYCHILD PROTOCOL
“A REGISTRY, ELIGIBILITY SCREENING, BIOLOGY AND OUTCOME STUDY”
open to eligible people ages up to 25 years
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Sacramento, California and other locations
Our lead scientists for Myeloproliferative Neoplasms research studies include Marcio H. Malogolowkin.
Last updated: